Check for updates

REVIEW

Harnessing the protective potential of HIV-1 neutralizing antibodies [version 1; peer review: 2 approved]

S Abigail Smith², Cynthia A Derdeyn^{1,2}

¹Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, 30322, USA

²Yerkes National Primate Research Center, Atlanta, Georgia, 30322, USA

V1 First published: 05 Jan 2016, 5(F1000 Faculty Rev):20
<https://doi.org/10.12688/f1000research.7254.1>

Latest published: 05 Jan 2016, 5(F1000 Faculty Rev):20
<https://doi.org/10.12688/f1000research.7254.1>

Abstract

Recent biological, structural, and technical advances are converging within the HIV-1 vaccine field to harness the power of antibodies for prevention and therapy. Numerous monoclonal antibodies with broad neutralizing activity against diverse HIV-1 isolates have now been identified, revealing at least five sites of vulnerability on the envelope (Env) glycoproteins. While there are practical and technological barriers blocking a clear path from broadly neutralizing antibodies (bNAb) to a protective vaccine, this is not a dead end. Scientists are revisiting old approaches with new technology, cutting new trails through unexplored territory, and paving new roads in the hopes of preventing HIV-1 infection. Other promising avenues to capitalize on the power of bNAbs are also being pursued, such as passive antibody immunotherapy and gene therapy approaches. Moreover, non-neutralizing antibodies have inhibitory activities that could have protective potential, alone or in combination with bNAbs. With a new generation of bNAbs, and a clinical trial that associated antibodies with reduced acquisition, the field is closer than ever to developing strategies to use antibodies against HIV-1.

Keywords

human immunodeficiency virus type 1 , HIV-1 neutralizing antibodies , broadly neutralizing antibody , antibody-mediated protection , antibody-mediated therapy

Open Peer Review

Approval Status

	1	2
version 1
05 Jan 2016		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **David C. Montefiori**, Duke University Medical Center, Durham, USA
2. **Michael Seaman**, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Cynthia A Derdeyn (cderdey@emory.edu)

Competing interests: The authors declare that they have no competing interests.

Grant information: CAD and SAS are supported by NIH-R01-AI58706.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Smith SA and Derdeyn CA. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Smith SA and Derdeyn CA. **Harnessing the protective potential of HIV-1 neutralizing antibodies [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):20 <https://doi.org/10.12688/f1000research.7254.1>

First published: 05 Jan 2016, 5(F1000 Faculty Rev):20 <https://doi.org/10.12688/f1000research.7254.1>

Introduction

Neutralizing antibodies against HIV-1 were first described early in the HIV-1 epidemic¹, raising hopes that a protective vaccine was in the immediate future. Yet 30 years later, only one vaccination regimen has shown any efficacy in humans to date², essentially in the absence of functional neutralizing antibody activity^{3,4}. Indeed, most vaccine approaches tested so far mainly elicit antibodies that can only neutralize T-cell line-adapted strains and the minor fraction of naturally occurring strains that exhibit a highly sensitive tier 1 neutralization phenotype⁴⁻⁸. This is because most naturally occurring HIV-1 isolates tend to mask vulnerable surfaces, making them much more difficult to neutralize, classified as possessing a tier 2 or 3 phenotype⁹⁻¹¹. Stopping these neutralization-resistant, genetically diverse HIV-1 strains, which constitute the majority of the current global pandemic, will require an approach that successfully targets one or more regions of the trimeric envelope glycoprotein (Env) spike that are vulnerable to neutralization on most tier 2 viruses. However, all broadly neutralizing antibodies (bNAbs) identified thus far possess one or more unusual features¹², suggesting that they will be difficult to generate via vaccination. To overcome this and other potential obstacles, the HIV-1 research community is now moving forward along two major paths: (1) developing novel strategies to elicit antibodies capable of broadly and potently neutralizing clinically relevant, genetically diverse HIV-1 strains and (2) combining knowledge of bNAbs with modern technologies to create protective alternatives and therapeutic options (Figure 1).

Innovative application of bNAbs for HIV prevention and therapy

During natural HIV-1 infection, most individuals develop antibodies with some level of heterologous neutralization breadth^{13,14}, although only a small fraction of these individuals go on to develop high titers of the most extraordinary bNAbs¹⁵. A focused effort to recover monoclonal antibodies from these rare individuals with very potent

and broad plasma-neutralizing activity has led to a collection of a few dozen bNAbs, defined as having the ability to neutralize more than 60% of the variants in multi-clade HIV-1 Env panels at a concentration of less than 50 µg/ml^{12,16}. In turn, these discoveries have led to the identification of five regions on the viral Env trimer that are accessible to bNAbs: the CD4-binding site (CD4bs), the gp120 V1V2 hyper-variable domain, a glycan patch centered on the base of the gp120 V3 domain, the gp120 and gp41 interface, and the membrane proximal external region (MPER) of gp41. These discoveries have collectively bolstered optimism that bNAbs could also be elicited by vaccination.

However, genetic and structural characterizations of the most promising bNAbs have revealed substantial obstacles to eliciting them through vaccination. Although HIV-1 bNAbs can arise from several immunoglobulin germline precursors, they have unusual features such as high levels of somatic hypermutation, uncharacteristically long CDR H3 (complementarity determining region H3) domains, and in some cases polyreactivity¹². This may be because bNAbs must recognize complex epitopes that exhibit variation across HIV-1 strains and are often composed of both glycan and peptide¹⁷⁻²¹. Moreover, HIV-1 Env protein immunogens often do not readily bind and activate the germline precursors that have been associated with bNAb development, complicating immunogen design²²⁻²⁶. To gain more insight into the ontogeny of bNAbs, recent studies identified individuals who developed neutralizing antibody breadth early in infection and tracked co-evolution of the autologous virus and antibody lineages²⁷⁻³⁰. Key features that drive bNAb development appear to be the presence of a specific antibody germline precursor, a viral Env that can engage it, and temporal exposure of the antibody lineage to an array of highly related Env variants presenting different versions of the same epitope. The proficiency with which an antibody can neutralize autologous escape variants seems to be directly correlated with its ability to neutralize genetically diverse

Figure 1. Three promising avenues for using HIV-1 broadly neutralizing antibodies (bNAbs) for protection and therapy. Each area of pursuit is shown, and potential obstacles are listed below. For vaccination, there are two approaches for generating immunogens that will face common barriers. Env, envelope glycoprotein; NHP, non-human primate.

isolates²⁹. Yet even within a successful bNAb lineage, there are antibodies that share the features associated with bNAb activity but do not acquire breadth^{29,31,32}. The observation that some antibodies follow an evolutionary path toward acquiring neutralization breadth, while others do not, has yet to be explained. Incorporating information from these longitudinal studies of bNAb development into the design of Env immunogens that mimic this naturally occurring, but rare, process will be challenging, since it is likely that other host and viral factors also influence bNAb development^{12,33}.

Now that the development of two bNAb lineages has been traced in natural infection and the initiating and mutated Env variants determined, panels of Env immunogens based on these pathways can be developed and tested. Then again, the most important considerations for evaluating these novel Env immunogen panels are ambiguous. Should the indication to move forward with a series of immunogens be marked by successful stimulation of a particular bNAb germline, or a bNAb-related specificity with any germline? What level of heterologous tier 2 neutralization should be considered a success? Should protection from viral challenge also be demonstrated? Although transgenic mice have been used to model bNAb induction^{34,35}, the rhesus macaque model remains the most relevant for HIV vaccine studies. But this model is not ideal. There is limited information about the development of neutralization breadth in HIV-1 Env-immunized or chimeric simian-human immunodeficiency virus (SHIV)-infected rhesus macaques^{36–40}, and the antibody germline repertoire of this species is similar but not identical to that of humans^{39,41}. Interestingly, Env-specific antibodies from immunized rhesus macaques that exhibited the highest somatic hypermutation levels arose from a single VH (immunoglobulin variable domain heavy-chain segment) gene³⁷. Furthermore, a high level of somatic hypermutation in VH was not associated with serum neutralization breadth. Studies of immunized rhesus macaques have also demonstrated that CD4bs antibodies can be elicited, but these antibodies do not exhibit breadth, possibly because their angle of approach differs from that of the VRC01-like CD4bs bNAb^{42,43}. Thus, it will be important to carefully consider similarities and differences among non-human primates and humans when evaluating strategies to elicit bNAbs.

Another uncertainty regarding testing naturally occurring bNAb-associated Env immunogens is what form of Env should be administered. Do immunogens that retain the native trimeric Env structure present more relevant epitopes than monomeric gp120 or gp140 proteins for eliciting antibodies with breadth? The best-characterized Env trimer to date, BG505 SOSIP.664, is capable of activating inferred germlines from bNAbs *in vitro*²⁶. However, thus far, immunization of rhesus macaques with the BG505 SOSIP.664 trimer has not induced cross-reactive tier 2 neutralizing antibody responses⁸. The BG505 trimer immunogen did elicit low titers of antibodies that neutralized the tier 2 autologous pseudovirus and higher titers of antibodies that neutralized tier 1 Env variants. In addition, rhesus macaques immunized with a different trimer produced an antibody response that was polyclonal even within those directed against a single target⁴². Additional Env trimers from different HIV-1 genetic subtypes (clades) of the virus are being generated and characterized⁴⁴ and this will lead to a greater selection of immunogens to build upon.

Another matter to consider is that a precursor B cell that is capable of initiating a bNAb lineage may be relatively rare within the immune repertoire. To highlight the low chance of activating a particular heavy chain (VH) germline, there are approximately 76 to 84 functional VH possibilities in the human genome. The VH3-30 family, which is found in the V1V2-targeted bNAb lineage CAP256-VRC26 described by Doria-Rose *et al.*²⁷ and Bhiman *et al.*²⁹, contains 19 different alleles⁴⁵. Furthermore, there are inherent biases for and against heavy chain families and even individual alleles within families. Stimulating a specific B cell out of so many possibilities, in a genetically diverse population, is a daunting task. Compounding the rarity of the initial B cell, even the unmutated common ancestor, may need to have acquired unique features, such as a long CDR H3, or unusual insertions/deletions. The CAP256-VRC26 bNAb lineage was initiated by an unmutated precursor that had an extraordinarily long CDR H3 region^{27,29}. At 35 to 37 amino acids, the CAP256-VRC26 CDR H3 regions are more than twice the average length for human antibodies, approximately 15 amino acids⁴⁶. These inherent obstacles will need to be taken into consideration when designing a vaccine strategy. Finally, a specific Env variant that is capable of activating this unique germline must be present. It seems unlikely that a randomly selected Env immunogen will elicit a bNAb lineage. In the case of CAP256-VRC26, a variant that evolved from a superinfecting virus, but not the primary infecting virus quasispecies, initiated the bNAb lineage²⁹. The site of recognition on the antigen(s) by that initial antibody precursor also seems to be important, as different pathways to neutralization breadth were described for V1V2- and CD4bs-targeted bNAbs, the latter of which required a second helped antibody lineage^{27,28}.

Even with more knowledge about bNAbs and how they develop, the barriers standing in the way of an HIV vaccine are formidable. Avenues that are being explored independently of a vaccine are passive administration of bNAbs for immunotherapy and prevention. With a newer generation of bNAbs, an older idea such as passive immunotherapy might be more effective. The process of selecting bNAbs to advance into the clinical pipeline will require a careful assessment of multiple antibody properties, including their stabilities, pharmacokinetic profiles, and safety. One phase I trial of bNAb VRC01, which targets the CD4bs, has been conducted evaluating both intravenous and subcutaneous administration. This study indicated that both delivery routes were safe; however, subcutaneous delivery may be limited by the dosing required for adults and may be more suitable for infants⁴⁷. Caskey *et al.* infused variable doses of 3BNC117, which also targets the CD4bs, into healthy controls and HIV⁺ patients⁴⁸. This monoclonal antibody therapy was well tolerated, and all of the HIV⁺ patients who received the highest dose experienced significant decreases in viral load. Predictably, in some patients, a familiar specter emerged: mutations present within the patients' viral quasispecies facilitated escape from 3BNC117 neutralization. Thus, like the scenario that successful antiretroviral drug therapy requires the use of several different inhibitors, passive immunotherapy will likely require the use of a cocktail of bNAbs that target distinct regions of Env. An additional consideration is that bNAbs do not always exhibit complete neutralization *in vitro*. In some cases, a subfraction of virions exists that is refractory to inhibition. This "incomplete neutralization" phenomenon has been attributed to heterogeneity in virion-associated Env glycosylation,

or conformation within the genetically clonal virus population, or both^{49,50}. bNAbs that are more tolerant of this type of variation are more likely to achieve complete neutralization, but this is also dependent upon the properties of the Env variant itself⁴⁹. Recently, for bNAbs that are capable of complete viral neutralization, it was shown that the slope of the neutralization curve could be an important determinant of the therapeutic potential of a particular bNAb and should be considered along with breadth and potency⁵⁰. This study also revealed that CD4bs and V3 base/glycan-targeted bNAbs, because of their high inhibitory potential, could be especially beneficial for immunotherapy.

Besides viral escape, other roadblocks to the successful and widespread implementation of passive immunotherapy are the cost and logistics associated with the mass production of a sufficient amount of bNAbs. Researchers are now using tobacco plants to produce an arsenal of HIV-1 bNAbs^{51,52}. The tobacco plants have been genetically modified to modulate antibody glycosylation and sulfation and allow antibody production to be ramped up to an industrial scale. A cocktail of monoclonal antibodies produced in this manner was used as an emergency treatment for Ebola during the 2014 epidemic^{53,54}. With the recovery of so many different HIV-1 bNAbs, some with extraordinary potency and breadth, immunotherapy could also have an important role to play in treating HIV-1 infection.

Given the uncertainty of whether bNAbs can be induced via a vaccine, researchers are also venturing into the uncharted territories of gene therapy, which combined with the new generation of bNAbs has opened up new options. Gene therapy protocols are being developed to potentially deliver bNAb over long periods of time; the idea is that a sufficient amount of bNAbs present at the time of exposure might be able to prevent HIV-1 infection altogether. This concept is supported by numerous observations that passive administration of bNAbs to rhesus macaques at high concentrations can prevent mucosal SHIV infection⁵⁵. One question that remains is whether bNAbs generated by passive administration, gene therapy, and immunization will all have the same protective potential^{56–59}. As proof of concept, adeno-associated virus (AAV) has recently been used as a vector to deliver the genetic material that encodes VRC07, a CD4bs bNAb, into humanized mice and rhesus macaques. Both animal models showed that this mode of antibody delivery could protect from a mucosal challenge^{60,61}. Gardner *et al.* took this concept a step further, creating a novel chimeric antibody that is more potent and broad than even the best bNAbs⁶². This construct, eCD4-Ig, combines the broad recognition ability of CD4 (a receptor essential for all HIV-1, HIV-2, and simian immunodeficiency virus [SIV] variants) with a sulfated peptide that mimics the co-receptor CCR5. When AAV was used to deliver eCD4-Ig to rhesus macaques, the animals showed no sign of infection for the duration of the study (40 weeks post-therapy), despite escalating intravenous challenges. This represents a stellar example of how a strong basic research program can lead to innovative and promising approaches^{63–67}.

Given the difficulties in delivering bNAbs discussed above or in eliciting them by vaccination, some researchers are staying the

course to a vaccine by developing approaches to protect against HIV-1 without bNAb. One alternative is to generate antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC). Although the RV144 vaccine trial generated antibody responses with minimal neutralization capabilities, these same antibodies were capable of mediating ADCC⁶⁸. Thus, it is worth revisiting the protective potential of non-neutralizing antibodies, which could be more amenable to elicitation by a vaccine^{57,69–71}. Another option is to delve into the antibody ontogeny of more HIV-1-infected patients, looking for more attainable antibody goals as well as identifying viral and immunological roadblocks that prevent the development of neutralization breadth. Rather than trying to coax the immune system into making rare antibodies, one could focus on strategies to elicit antibodies with moderate breadth, limited somatic hypermutation, typical CDR H3 lengths, and commonly used VH germline precursors⁷². Perhaps eliciting combinations of these more common types of antibodies would provide some level of protection in the end.

Summary

The past several years have seen major advances in terms of antibody-mediated protection and therapy against HIV-1. bNAbs, though rare, are generated in multiple HIV-1-infected individuals. Insight into bNAb ontogeny during natural infection has revealed novel strategies for vaccination, but at the same time these studies have highlighted the difficulties that will need to be overcome. Other avenues for passive therapy and protection have become possible because of the new generation of bNAbs, some of which can neutralize up to 90% of genetically diverse isolates tested and could be even more effective when combined optimally⁷³. Innovative design of Env immunogens, chimeric antibodies, and enhanced bNAbs may also yield protective or therapeutic benefits. Finally, bNAb-independent approaches that involve more moderate neutralization breadth or non-neutralizing effector functions may also hold promise.

Abbreviations

AAV, adeno-associated virus; ADCC, antibody-dependent cellular cytotoxicity; bNAb, broadly neutralizing antibody; CD4bs, CD4-binding site; CDR H3, complementarity determining region H3; Env, envelope glycoprotein; SHIV, chimeric simian-human immunodeficiency virus; V1V2, gp120 hyper-variable domains 1 and 2; V3, gp120 variable domain 3; VH, immunoglobulin variable domain heavy-chain segment.

Competing interests

The authors declare that they have no competing interests.

Grant information

CAD and SAS are supported by NIH-R01-AI58706.

I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Weiss RA, Clapham PR, Cheingsong-Popov R, *et al.*: **Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.** *Nature*. 1985; **316**(6023): 69–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, *et al.*: **Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.** *N Engl J Med*. 2009; **361**(23): 2209–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
3. Haynes BF, Gilbert PB, McElrath MJ, *et al.*: **Immune-correlates analysis of an HIV-1 vaccine efficacy trial.** *N Engl J Med*. 2012; **366**(14): 1275–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
4. Montefiori DC, Karnasuta C, Huang Y, *et al.*: **Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.** *J Infect Dis*. 2012; **206**(3): 431–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Golding H, D'Souza MP, Bradac J, *et al.*: **Neutralization of HIV-1.** *AIDS Res Hum Retroviruses*. 1994; **10**(6): 633–43.
[Publisher Full Text](#)
6. Matthews TJ: **Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.** *AIDS Res Hum Retroviruses*. 1994; **10**(6): 631–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Mascola JR, Snyder SW, Weislow OS, *et al.*: **Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.** *J Infect Dis*. 1996; **173**(2): 340–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Sanders RW, van Gils MJ, Derking R, *et al.*: **HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.** *Science*. 2015; **349**(6244): aac4223.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Kwong PD, Wyatt R, Majeed S, *et al.*: **Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.** *Structure*. 2000; **8**(12): 1329–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Kwong PD, Doyle ML, Casper DJ, *et al.*: **HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.** *Nature*. 2002; **420**(6916): 678–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Guttman M, Cupo A, Julien JP, *et al.*: **Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env.** *Nat Commun*. 2015; **6**: 6144.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Moore PL, Williamson C, Morris L: **Virological features associated with the development of broadly neutralizing antibodies to HIV-1.** *Trends Microbiol*. 2015; **23**(4): 204–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Hraber P, Seaman MS, Bailer RT, *et al.*: **Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.** *AIDS*. 2014; **28**(2): 163–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Gray ES, Madiga MC, Hermanus T, *et al.*: **The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4⁺ T cell decline and high viral load during acute infection.** *J Virol*. 2011; **85**(10): 4828–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Simek MD, Rida W, Priddy FH, *et al.*: **Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.** *J Virol*. 2009; **83**(14): 7337–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Eroshkin AM, LeBlanc A, Weekes D, *et al.*: **bNAber: database of broadly neutralizing HIV antibodies.** *Nucleic Acids Res*. 2014; **42**(Database issue): D1133–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Scharf L, Wang H, Gao H, *et al.*: **Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env.** *Cell*. 2015; **162**(6): 1379–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. McLellan JS, Pancera M, Carrico C, *et al.*: **Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.** *Nature*. 2011; **480**(7377): 336–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
19. Julien JP, Sok D, Khayat R, *et al.*: **Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.** *PLoS Pathog*. 2013; **9**(5): e1003342.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Blattner C, Lee JH, Sliepen K, *et al.*: **Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.** *Immunity*. 2014; **40**(5): 669–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
21. Huang J, Kang BH, Pancera M, *et al.*: **Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.** *Nature*. 2014; **515**(7525): 138–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. McGuire AT, Hoot S, Dreyer AM, *et al.*: **Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.** *J Exp Med*. 2013; **210**(4): 655–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. McGuire AT, Glenn JA, Lippy A, *et al.*: **Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.** *J Virol*. 2014; **88**(5): 2645–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Jardine J, Julien JP, Menis S, *et al.*: **Rational HIV immunogen design to target specific germline B cell receptors.** *Science*. 2013; **340**(6133): 711–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Hoot S, McGuire AT, Cohen KW, *et al.*: **Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.** *PLoS Pathog*. 2013; **9**(1): e1003106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Sliepen K, Medina-Ramírez M, Yasmeen A, *et al.*: **Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.** *Virology*. 2015; **486**: 116–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Doria-Rose NA, Schramm CA, Gorman J, *et al.*: **Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.** *Nature*. 2014; **509**(7498): 55–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
28. Liao HX, Lynch R, Zhou T, *et al.*: **Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.** *Nature*. 2013; **496**(7446): 469–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Bhiman JN, Anthony C, Doria-Rose NA, *et al.*: **Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.** *Nat Med*. 2015; **21**(11): 1332–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
30. Gao F, Bonsignori M, Liao HX, *et al.*: **Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.** *Cell*. 2014; **158**(3): 481–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Walker LM, Huber M, Doores KJ, *et al.*: **Broad neutralization coverage of HIV by multiple highly potent antibodies.** *Nature*. 2011; **477**(7365): 466–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Scheid JF, Mouquet H, Feldhahn N, *et al.*: **Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.** *Nature*. 2009; **458**(7238): 636–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. Derdeyn CA, Moore PL, Morris L: **Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.** *Curr Opin HIV AIDS*. 2014; **9**(3): 210–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Dosenovic P, von Boehmer L, Escolano A, *et al.*: **Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.** *Cell*. 2015; **161**(7): 1505–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Jardine JG, Ota T, Sok D, *et al.*: **HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.** *Science*. 2015; **349**(6244): 156–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Kraft Z, Derby NR, McCaffrey RA, *et al.*: **Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.** *J Virol*. 2007; **81**(12): 6402–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Francica JR, Sheng Z, Zhang Z, *et al.*: **Analysis of immunoglobulin transcripts and hypermutation following SHIV_{AD8} infection and protein-plus-adjuvant immunization.** *Nat Commun*. 2015; **6**: 6565.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Shingai M, Donau OK, Schmidt SD, *et al.*: **Most rhesus macaques infected with the CCR5-tropic SHIV_{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains.** *Proc Natl Acad Sci U S A*. 2012; **109**(48): 19769–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Sundling C, Li Y, Huynh N, *et al.*: **High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.** *Sci Transl Med*. 2012; **4**(142): 142ra96.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Sundling C, Forsell MN, O'Dell S, *et al.*: **Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.** *J Exp Med*. 2010; **207**(9): 2003–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. Sundling C, Zhang Z, Phad GE, *et al.*: **Single-cell and deep sequencing of**

- IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. *J Immunol.* 2014; 192(8): 3637–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. **F** Phad GE, Vázquez Bernat N, Feng Y, *et al.*: Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization. *J Immunol.* 2015; 194(12): 5903–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 43. **F** Tran K, Poulsen C, Guenaga J, *et al.*: Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. *Proc Natl Acad Sci U S A.* 2014; 111(7): E738–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. Julien J, Lee JH, Ozorowski G, *et al.*: Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. *Proc Natl Acad Sci U S A.* 2015; 112(38): 11947–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Lefranc MP: Nomenclature of the human immunoglobulin heavy (IGH) genes. *Exp Clin Immunogenet.* 2001; 18(2): 100–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Breden F, Lepik C, Longo NS, *et al.*: Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. *PLoS One.* 2011; 6(3): e16857.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. **F** Ledgerwood JE, Coates EE, Yamshchikov G, *et al.*: Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. *Clin Exp Immunol.* 2015; 182(3): 289–301.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. **F** Caskey M, Klein F, Lorenzi JC, *et al.*: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature.* 2015; 522(7557): 487–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 49. **F** McCoy LE, Falkowska E, Doores KJ, *et al.*: Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. *PLoS Pathog.* 2015; 11(8): e1005110.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 50. **F** Webb NE, Montefiori DC, Lee B: Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. *Nat Commun.* 2015; 6: 8443.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 51. **F** Loos A, Gach JS, Hackl T, *et al.*: Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. *Proc Natl Acad Sci U S A.* 2015; 112(41): 12675–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 52. Rosenberg Y, Sack M, Montefiori D, *et al.*: Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. *PLoS One.* 2013; 8(3): e58724.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Qiu X, Audet J, Wong G, *et al.*: Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. *Sci Transl Med.* 2012; 4(138): 138ra81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Olinger GG Jr, Pettitt J, Kim D, *et al.*: Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. *Proc Natl Acad Sci U S A.* 2012; 109(44): 18030–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. van Gils MJ, Sanders RW: *In vivo* protection by broadly neutralizing HIV antibodies. *Trends Microbiol.* 2014; 22(10): 550–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Burton SL, Kilgore KM, Smith SA, *et al.*: Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. *Proc Natl Acad Sci U S A.* 2015; 112(34): 10780–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. **F** Fouts TR, Bagley K, Prado IJ, *et al.*: Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. *Proc Natl Acad Sci U S A.* 2015; 112(9): E992–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 58. Carnathan DG, Wetzel KS, Yu J, *et al.*: Activated CD4⁺CCR5⁺ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. *Proc Natl Acad Sci U S A.* 2015; 112(2): 518–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. **F** Lewis GK, DeVico AL, Gallo RC: Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. *Proc Natl Acad Sci U S A.* 2014; 111(44): 15614–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 60. Saunders KO, Wang L, Joyce MG, *et al.*: Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. *J Virol.* 2015; 89(16): 8334–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Balazs AB, Ouyang Y, Hong CM, *et al.*: Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. *Nat Med.* 2014; 20(3): 296–300.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. **F** Gardner MR, Kattenhorn LM, Kondur HR, *et al.*: AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. *Nature.* 2015; 519(7541): 87–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 63. **F** Choe H, Li W, Wright PL, *et al.*: Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. *Cell.* 2003; 114(2): 161–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 64. Farzan M, Mirzabekov T, Kolchinsky P, *et al.*: Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. *Cell.* 1999; 96(5): 667–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Farzan M, Choe H, Vaca L, *et al.*: A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. *J Virol.* 1998; 72(2): 1160–4.
[PubMed Abstract](#) | [Free Full Text](#)
 66. **F** Huang C, Venturi M, Majeed S, *et al.*: Structural basis of tyrosine sulfation and V_H-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. *Proc Natl Acad Sci U S A.* 2004; 101(9): 2706–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 67. Xiang SH, Farzan M, Si Z, *et al.*: Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. *J Virol.* 2005; 79(10): 6068–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. **F** Bonsignori M, Pollara J, Moody MA, *et al.*: Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. *J Virol.* 2012; 86(21): 11521–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. Santra S, Tomaras GD, Warrier R, *et al.*: Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. *PLoS Pathog.* 2015; 11(8): e1005042.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Acharya P, Tolbert WD, Gohain N, *et al.*: Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. *J Virol.* 2014; 88(21): 12895–906.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Lewis GK, Finzi A, DeVico AL, *et al.*: Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. *Viruses.* 2015; 7(9): 5115–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. **F** Zolla-Pazner S: A critical question for HIV vaccine development: which antibodies to induce? *Science.* 2014; 345(6193): 167–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 73. Miglietta R, Pastori C, Venuti A, *et al.*: Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. *J Transl Med.* 2014; 12: 346.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Michael Seaman**

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center - Harvard Medical School, Boston, Massachusetts, 02115, USA

Competing Interests: No competing interests were disclosed.

2. **David C. Montefiori**

Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, 27710, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research